Support Line: 0800 002 9002
General Enquiries: 01223 870008
  »  Kidney Cancer News  »  Promise in US Trial for Advanced Metastatic RCC

Promise in US Trial for Advanced Metastatic RCC

by | Dec 20, 2017 | Kidney Cancer News | 0 comments

New data from a Phase 1 clinical trial shows that ARMO BioSciences‘  immunotherapy AM0010 (pegilodecakin), alone or in combination with immune checkpoint inhibitors, shows high and durable clinical responses in patients with advanced renal cell carcinoma (RCC).
The data were presented during the European Society of Medical Oncology (ESMO) Immuno Oncology Congress 2017, Geneva, Switzerland, on Dec. 8.
Aung Naing, MD, from The University of Texas MD Anderson Cancer Center delivered the presentation  “Efficacy of PEGylated Human IL-10 (AM0010) in Combination with anti-PD-1 Blockade in Patients (pts) with Metastatic Renal Cell Carcinoma (mRCC): A phase 1b Trial.
The ongoing Phase 1b trial (NCT02009449) is an open-label, dose-escalation study designed to evaluate both the safety and tolerability of AM0010 in patients with advanced solid tumors, including metastatic renal cell carcinoma (mRCC).
When delivered alone, AM0010 induced an overall response rate of 25 percent. However, patients treated with AM0010, in combination with either Keytruda (pembrolizumab) or Opdivo (nivolumab), showed an overall response rate of 41 percent.
Combining AM0010 with either Keytruda or Opdivo showed no additional adverse effects compared to the monotherapy.
After a median follow-up of 2.5 years for patients in the Opdivo arm, and roughly one year for those in the Keytruda arm, the median overall survival has not been reached, meaning that more than half of patients in those groups are still alive.
Patients treated with AM010 plus Keytruda lived for a median of 16.7 months without worsening of their disease. In the Opdivo arm, more than half of patients are still alive and progression-free.
“While we are very pleased with the data we have generated to date in RCC, it is particularly exciting to see these high, durable responses in intermediate to poor risk advanced RCC patients who have received 2 or more prior therapies given the high unmet medical need for these patients,” Joseph Leveque, MD, chief medical officer of ARMO Biosciences, said in a press release. “In addition to the objective tumor responses, early survival data are also very encouraging.”
You can read the full article onimmuno-oncologynews.com here

<a href="https://www.kcuk.org.uk/author/mp/" target="_self">Malcolm Packer</a>

Malcolm Packer

Malcolm is Chief Executive Officer at Kidney Cancer UK and Kidney Cancer Scotland and has worked with the charity in various capacities for over 15 years.